2010 - TTS International Congress


This page contains exclusive content for the member of the following sections: TTS. Log in to view.

Optimizing Immediate Graft Function in Kidney Transplantation

92.8 - Gingko biloba extract (EGb 761) ameliorates kidney injury and promotes renal function recovery in a rat model of ischemia-reperfusion injury.

Presenter: Longshan, LIU, Guangzhou, People's Republic of China
Authors: LIU L., Wang C., LI W., DENG S., ZENG W., Teng L., HE X.

GINGKO BILOBA EXTRACT (EGB 761) AMELIORATES KIDNEY INJURY AND PROMOTES RENAL FUNCTION RECOVERY IN A RAT MODEL OF ISCHEMIA-REPERFUSION INJURY.

OPTIMIZING IMMEDIATE GRAFT FUNCTION IN KIDNEY TRANSPLANTATION

L. Liu1, C. Wang1, W. Li2, S. Deng3, W. Zeng2, L. Teng4, X. He1
1Organ Transplantation Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou/CHINA, 2Lab Of Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou/CHINA, 3Organ Transplant Center, The First Affiliated Hosptial, Sun Yat-sen University, Guangzhou/CHINA, 4Department Of Organ Transplantation, First Affiliated Hospital, Sun Yat-sen University, Guangzhou/CHINA

Body: Introduction Increasing studies have proven that EGb 761, a standardized extract of Gingko biloba, has protective effect against cerebral ischemia injury. Only two studies observed the effect of EGb 761 on renal ischemia-reperfusion injury (IRI), which indicated EGb 761 ameliorated renal injury at four or six hours after reperfusion. The present study was designed to investigate the effect of EGb 761 on immediate injury and subsequent function recovery after suffering renal IRI. Methods and Results Adult male Sprague-Dawley rats were used to induce renal IRI. Left renal pedicles were occluded with a vascular clamp. After 50 minutes of ischemia, the clamp was released and contralateral kidney was nephrectomized. Rats in sham group underwent renal pedicle isolation without occlusion. EGb 761 (50 mg/kg/day) and its vehicle were continuously administered to renal IRI rats once daily, from two days before operation (day -2) to 11 days after reperfusion (day 11). As results: (1) sCr increased to peak level at day 3 in all IRI rats. Subsequently, sCr deceased to normal level (sham group) at day 7 in EGb treated rats, while at day 11 in vehicle treated rats. Compared to vehicle group, EGb group presented lower sCr at day 3 and day 7 (p<0.05). (2) CrCl decreased to trough level at day 3 in all IRI rats. Subsequently, CrCl in EGb treated rats increased to normal level (sham group) at day 7, however CrCl didn’t reach normal level in vehicle treated rats. Compared to vehicle group, EGb group presented higher CrCl at day 7 and day 11 (p<0.01). (3) HE staining at day 3 showed attenuated renal injury and lower Paller score (estimating renal tubular damage, p<0.05) in EGb group than in vehicle group. Next, we examined cellular and molecular parameters which play important roles in renal IRI. At 6 h post reperfusion, mRNA level of inflammatory factors including TNF-α, IL-β, IL-6 and MCP-1, was lower in EGb group than in vehicle control (p<0.05). At 24 h after reperfusion, compared to vehicle group, malondialdehyde (MDA) significantly decreased in EGb group (p<0.05). Moreover, the activity of superoxide dismutase (SOD) and reduced glutathione (GSH) increased in EGb group (p<0.05). At 6 h and 24 h after reperfusion, iNOS mRNA level and protein expression was significantly lower in EGb treated rats than in vehicle treated rats (p<0.05). Nitrite/nitrate and myeloperoxidase (MPO) content in EGb group were significantly lower than in vehicle control (p<0.05). ICAM-1 and VCAM-1 were found extensively expressing in all I/R kidney by immunostaining, while EGb 761 treated rats presented lower intensity. All the above parameters came from kidney tissues, except nitrite/nitrate analysis examining serum NO content. Conclusion EGb 761 can attenuate immediate kidney injury and promote its function recovery after renal ischemia-reperfusion injury in rats. The inhibition of inflammation, iNOS induction and oxidative stress may contribute to its renal protective effect.

Disclosure: All authors have declared no conflicts of interest.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada